$LH

Kyle Kathryn W sold $26K of LH

Kyle Kathryn W (EVP, Chief Legal Officer) sold 92 shares of LABCORP HOLDINGS INC. (LH) at $286.19 on 2026-07-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Kyle Kathryn W
Published Jul 6, 2026, 1:37 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 6, 2026, 1:39 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LH
Neutral
high confidence
Mentioned
$LH
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LHNeutralLow
01

Why it matters

Because the sale is explicitly under a pre-arranged Rule 10b5-1 plan, it typically reflects scheduled liquidity rather than new negative information.

02

Market read

A small, scheduled insider sale is unlikely to drive trading decisions beyond routine monitoring.

03

What to watch

The article provides only one transaction size and does not include prior insider activity frequency, option exercises, or any concurrent buys.

Relevance 2/10Novelty 3/10Timing: Filed July 6, covering a sale executed July 2

Background

The disclosure is an SEC Form 4 insider transaction by Kyle Kathryn W (EVP, Chief Legal Officer) for LABCORP HOLDINGS INC.

Company-level read

Ticker impact

$LHNeutralHigh confidence
Context

Form 4 shows LH’s EVP & Chief Legal Officer sold 92 shares at $286.19 on a 10b5-1 plan, totaling $26,329.48.

Expected impact

Minimal near-term impact; any effect is likely sentiment-only and short-lived.

Evidence & confidence

The filing is an open-market sale by an insider with an explicitly stated 10b5-1 plan and small share count/value relative to typical market moves.

Market effects

No clear sector read-through from a single, small 10b5-1 insider sale.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, repeated insider selling can coincide with internal caution; traders may still monitor for a pattern.

Key entities

  • LABCORP HOLDINGS INC.

    Subject of the Form 4 insider transaction disclosure.

  • Kyle Kathryn W

    EVP, Chief Legal Officer who executed the open-market sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$RDNTHighAI 8/10

Testing & Diagnostics Services Stocks Q2 Results: Benchmarking Guardant Health (NASDAQ:GH)

Guardant Health, RadNet (NASDAQ:RDNT), Labcorp (NYSE:LH), NeoGenomics (NASDAQ:NEO), and Quest (NYSE:DGX) reported Q2 results. RadNet saw 25% revenue growth, beating estimates. Labcorp's revenue grew 5.8%, meeting expectations but underperforming peers. NeoGenomics and Quest both beat estimates with 11.2% and 10.2% revenue growth, respectively. Stocks have risen since reporting.

$LHMedAI 8/10

Labcorp to offer FDA-cleared Elecsys pTau-217 Alzheimer's test

Labcorp (LH) will offer the FDA-cleared Elecsys pTau-217 blood test, developed by Roche Diagnostics, to detect Alzheimer's-related amyloid pathology in individuals aged 55+ with cognitive decline. This is the first FDA-cleared single-biomarker test for both ruling in and out amyloid pathology, setting it apart from other options.

$LHMed

Why is Labcorp stock sliding today?

Labcorp (LH) stock fell 4.3% to $307.43 after its 2026 Investor Day, where it reaffirmed revenue guidance of $14.71B-$14.83B and EPS growth of 8.5%-11.5%. The market expected a guidance raise, and the lack of upside led to profit-taking. Broader market declines also pressured the stock.